Rockefeller Capital Management
OVID icon

Rockefeller Capital Management’s Ovid Therapeutics OVID Stock Holding History

Rockefeller Capital Management’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$10K Hold
4,000
– – ﹤0.01% 4177
2026
Q2 		$10.8K Hold
4,000
– – ﹤0.01% 3991
2026
Q1 		$8.88K Hold
4,000
– – ﹤0.01% 4041
2025
Q4 		$6.52K Buy
+4,000
New +$6.16K ﹤0.01% 3982

Other funds holding OVID

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Eventide Asset Management
Eventide Asset Management Boston, Massachusetts $7.14B AUM 65.02% 1-Year Est. Return
Affinity Asset Advisors
Affinity Asset Advisors New York $2.46B AUM 196.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $71.4B AUM 33.43% 1-Year Est. Return
Silverarc Capital Management
Silverarc Capital Management Boston, Massachusetts $854M AUM 179.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM

Rockefeller Capital Management's OVID Position: Q3 2026 in Review

Rockefeller Capital Management held its Ovid Therapeutics (OVID) position steady in Q3 2026 at 4,000 shares worth $10K. The position accounts for ﹤0.01% of the portfolio, ranked #4177.

Rockefeller Capital Management first reported a position in OVID in Q4 2025 and has held it in 4 quarters since. The position peaked at $10.8K in Q2 2026. 81 funds tracked by Wall St. Rank hold OVID as of Q3 2026.

  • Rockefeller Capital Management held 4,000 shares of Ovid Therapeutics worth $10K as of Q3 2026.
  • Rockefeller Capital Management left its Ovid Therapeutics share count unchanged in Q3 2026.
  • Ovid Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q3 2026, its #4177 holding.
  • Rockefeller Capital Management first reported a position in Ovid Therapeutics in Q4 2025 and has held it in 4 quarters since.
  • Rockefeller Capital Management's Ovid Therapeutics position peaked at $10.8K in Q2 2026.
  • 81 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q3 2026.

Based on Rockefeller Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.